ClinicalTrials.gg
CompletedNCT02468193Updated May 6, 2020Results posted

Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome

A Phase 2 interventional study of Osilodrostat in Cushing's Syndrome, Ectopic Corticotropin Syndrome and Adrenal Adenoma, sponsored by Novartis Pharmaceuticals. Completed at 4 sites in Japan. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-05-06.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The study aim was to investigate the efficacy and safety of Osilodrostat in patients with Cushing's syndrome due to causes other than Cushing's disease in Japan.

Read the detailed description

This was a Phase II, single arm, open-label, dose titration, multi-center study which consisted of two distinct Study Periods plus an optional extension period in non-CD patients with CS. The 3 Study Periods (two distinct Study Periods plus an optional extension period) were as follows:

Study Period I [Week 0 (Day 1) to Week-12]: Study Period I was the dose titration period to achieve a stable therapeutic dose and to assess the efficacy and safety of osilodrostat.

The dosing regimen of osilodrostat in this study was titrated according to the following escalation sequence: osilodrostat 2 mg bid, 5 mg bid, 10 mg bid, 20 mg bid, and 30 mg bid. Dose adjustments were based on the serum cortisol values measured by the local lab at each site. Osilodrostat titration was done weekly for the initial 4-weeks, up to a maximum dose of 10 mg bid.

The mean of three 24-hour UFC (mUFC) values were measured to evaluate the efficacy in this period.

Study Period II (After Week-12 to Week-48): Study Period II was the period to assess the sustainability of efficacy and long term safety.

During Study Period II, only patients who tolerated and agreed to continue osilodrostat treatment continued on the study. The patient was administered with the stable therapeutic dose which was achieved in the Study Period I.

Optional extension period (After Week-48): Patients who continued to receive clinical benefit, as assessed by the study Investigator and who wished to enter the extension period were reconsented at Week-48. Patients who entered the extension period continued to be treated with the study drug without interruption to be assessed for efficacy and safety. Patients who continued to benefit from study treatment as assessed by the study investigator and who completed Week-72 were offered to participate in a separate long-term safety follow-up study. The optional extension period ended after all patients had completed Week-72 or had discontinued early.

Post-treatment Follow-up: All patients had 30 days safety follow-up after the last dose of study treatment.

02

Conditions studied

  • Cushing's Syndrome
  • Ectopic Corticotropin Syndrome
  • Adrenal Adenoma
  • Adrenal Carcinoma
  • AIMAH
  • PPNAD

Keywords

  • Cushing's syndrome
  • osilodrostat
  • LCI699
  • ectopic corticotropin syndrome
  • adrenal adenoma
  • adrenal carcinoma
  • ACTH-Independent Macronodular Adrenal Hyperplasia
  • AIMAH
  • Primary Pigmented Nodular Adrenal Dysplasia
  • PPNAD
03

In context

Cushing Syndrome

123 studies on the registry are indexed under Cushing Syndrome; 42 are open to participants now.

This study's enrollment of 9 is below the median of 44 across 58 interventional studies indexed under Cushing Syndrome.

Browse Cushing Syndrome studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with confirmed Cushing's syndrome [i.e. ectopic corticotropin syndrome, adrenal adenoma, adrenal carcinoma, ACTH-Independent Macronodular Adrenal Hyperplasia (AIMAH), or Primary Pigmented Nodular Adrenal Dysplasia (PPNAD)]
  • For patients on medical treatment for hypercortisolism due to Cushing's syndrome, the had to be completed prior to baseline efficacy assessments

Exclusion criteria

Exclusion Criteria:

  • Patients with Cushing's disease
  • History of to osilodrostat or to drugs of similar chemical classes
  • History of of any organ system, treated or untreated, within the past 5 years
  • Patients receiving treatment for within 4 weeks or ≤5 x half-life of the agent (whichever is longer) before first dose of osilodrostat
  • Patients with risk factors for prolongation or Torsade de Pointes
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Osilodrostat

    Patients in this arm took the study drug, osilodrostat.

    Drug: Osilodrostat

Interventions

  • Osirodrostat 1mg, 5mg \& 10mg in the form of film-coated tablets was used for oral administration.

    Also known as: LCI699

06

What researchers measure

Primary outcomes

  1. Percent Change in the Mean Urine Free Cortisol (mUFC) at the Individual Level at Week 12

    Percent change from baseline in the mUFC at the individual patient level

    Time frame: Baseline, 12 weeks

Secondary outcomes

  1. Percent Change From Baseline in the mUFC at Individual Patient Level at Week 24 (Day 169) and Week 48 (Day 337)

    Percent change from baseline in the mUFC at the individual patient level

    Time frame: Baseline, Week 24 (day 169) and Week 48 (day 337)

  2. Absolute Change From Baseline in the mUFC at Week 12 (Day 85), Week 24 (Day 169) and Week 48 (Day 337)

    Absolute change from baseline in the mUFC

    Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)

  3. Percentage Change From Baseline in the mUFC at Week 12 (Day 85), Week 24 (Day 169) and Week 48 (Day 337)

    Percent change from baseline in the mUFC

    Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)

  4. Percentage of Participants With mUFC Response of Complete, Partial, and Overall Response

    Complete response rate = percentage of participants who had mUFC≤ ULN; Partial response rate = Percentage of participants who had mUFC\>ULN and at least 50% reduction from baseline in mUFC. Overall response rate = Percentage of participants who had mUFC ≤ ULN or at least 50% reduction from baseline.

    Time frame: 12, 24 and 48 weeks

  5. Absolute Change From Baseline in Morning Serum Cortisol at Individual Level

    Absolute change from baseline in morning serum cortisol at the individual patient level

    Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)

  6. Percentage Change From Baseline in Morning Serum Cortisol at Individual Level

    Percentage change from baseline in morning serum cortisol at the individual patient level

    Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)

  7. Absolute Change From Baseline in ACTH and Other Adrenal Steroid Hormones at Individual Level

    Absolute change from baseline in several steroid hormones at individual levels: ACTH, Serum 11-deoxycorticosterone, Aldosterone, Estradiol

    Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)

  8. Percentage Change From Baseline in ACTH and Other Adrenal Steroid Hormones at Individual Level

    Percent change from baseline in several steroid hormones at individual levels: ACTH, Serum 11-deoxycorticosterone, Aldosterone, Estradiol

    Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)

  9. Absolute Change From Baseline in Other Adrenal Steroid Hormones at Individual Levels

    Absolute change from baseline in several steroid hormones at individual levels: Serum 11-deoxycortisol, Testosterone

    Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)

  10. Percentage Change From Baseline in Other Adrenal Steroid Hormones at Individual Levels

    Percent change from baseline in several steroid hormones at individual levels: Serum 11-deoxycortisol, Testosterone

    Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)

  11. Absolute Change From Baseline in Cardiovascular-related Metabolic Parameter, Fasting Glucose, at Individual Level

    Absolute change in cardiovascular-related metabolic parameter fasting glucose, associated with Cushing's syndrome (CS)

    Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)

  12. Percentage Change From Baseline in Cardiovascular-related Metabolic Parameter, Fasting Glucose, at Individual Level

    Percentasge change in cardiovascular-related metabolic parameter fasting glucose, associated with Cushing's syndrome (CS)

    Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)

  13. Absolute Change From Baseline in Cardiovascular-related Metabolic Parameter, HbA1c, at Individual Level

    Absolute change in cardiovascular-related metabolic parameter HbA1c associated with Cushing's syndrome (CS)

    Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)

  14. Percentage Change From Baseline in Cardiovascular-related Metabolic Parameter, HbA1c, at Individual Level

    Percentage change in cardiovascular-related metabolic parameter HbA1c associated with Cushing's syndrome (CS)

    Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)

  15. Absolute Change From Baseline in Cardiovascular-related Metabolic Parameters, Cholesterol, HDL Cholesterol, LDL Cholesterol & Triglycerides, at Individual Level

    Absolute change in cardiovascular-related metabolic parameters: cholesterol, HDL cholesterol, LDL cholesterol \& triglycerides, associated with Cushing's syndrome (CS)

    Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)

  16. Percentage Change From Baseline in Cardiovascular-related Metabolic Parameters, Cholesterol, HDL Cholesterol, LDL Cholesterol & Triglycerides, at Individual Level

    Percent change in cardiovascular-related metabolic parameters: cholesterol, HDL cholesterol, LDL cholesterol \& triglycerides, associated with Cushing's syndrome (CS)

    Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)

  17. Absolute Change From Baseline in Cardiovascular-related Metabolic Parameter, BMI, at Individual Level

    Absolute change in cardiovascular-related metabolic parameter: BMI, associated with Cushing's syndrome (CS)

    Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)

  18. Percentage Change From Baseline in Cardiovascular-related Metabolic Parameter, BMI, at Individual Level

    Percent change in cardiovascular-related metabolic parameter: BMI, associated with Cushing's syndrome (CS)

    Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)

  19. Absolute Change From Baseline in Cardiovascular-related Metabolic Parameter, Waist Circumference, at Individual Level

    Absolute change in cardiovascular-related metabolic parameter: Waist circumference, associated with Cushing's syndrome (CS)

    Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)

  20. Percentage Change From Baseline in Cardiovascular-related Metabolic Parameter, Waist Circumference, at Individual Level

    Percent change in cardiovascular-related metabolic parameter: Waist circumference, associated with Cushing's syndrome (CS)

    Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)

  21. Absolute Change From Baseline in Cardiovascular-related Metabolic Parameter, Sitting Blood Pressure (BP) at Individual Level

    Absolute change in cardiovascular-related metabolic parameter: sitting systolic BP \& sitting diastolic BP, associated with Cushing's syndrome (CS)

    Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)

  22. Percentage Change From Baseline in Cardiovascular-related Metabolic Parameter, Sitting Blood Pressure (BP) at Individual Level

    Percentage change in cardiovascular-related metabolic parameter: sitting systolic BP \& sitting diastolic BP, associated with Cushing's syndrome

    Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)

  23. Total Scores in Patient-Reported Outcomes Health-related Quality of Life (QoL) as Assessed by Cushing QoL at Individual Level

    The Cushing's Disease Health-Related Quality of Life Questionnaire (Cushing QoL) (version 1.0) was developed to evaluate quality of life in patients with Cushing's syndrome (Webb et al 2008). The Cushing QoL is comprised of 12 items that capture patient responses on seven concepts: daily activities, healing and pain, mood and self-confidence, social concerns, physical appearance, memory and concern about the future. Each questionnaire of the Cushing QOL has a scale of 1-5 where '1' corresponding to 'Always' or 'Very much' and '5' to 'Never' or 'Not at all'. The lower the score, the greater the impact on HRQoL. The score is the sum of all the item response and can range from 12 (worst) to 60 points (best).

    Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)

  24. Total Scores in Patient-Reported Outcomes Health-related Quality of Life (QoL) as Assessed by Beck Depression Inventory II (BDI-ll) Depression Score at Individual Level

    The Beck Depression Inventory II (BDI-II) is a patient reported instrument that consists of 21 items designed to assess the intensity of depression in clinical \& normal patients in the preceding two weeks. Each item is a list of four statements arranged in increasing severity about a particular symptom of depression. Each of 21 items corresponds to a symptom of depression and the sum of total score will be calculated where each item has a four-point scale ranging from 0 to 3, leading to a total score from zero to 63.

    Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)

  25. Plasma Concentrations of Osilodrostat (LCI699) at Week 0

    Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.

    Time frame: Week 0

  26. Plasma Concentrations of Osilodrostat (LCI699) at Week 1

    Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.

    Time frame: Week 1, 2 hours post-dose

  27. Plasma Concentrations of Osilodrostat (LCI699) at Week 2

    Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.

    Time frame: Week 2

  28. Plasma Concentrations of Osilodrostat (LCI699) at Week 3

    Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.

    Time frame: Week 3, 2 hours post-dose

  29. Plasma Concentrations of Osilodrostat (LCI699) at Week 4

    Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.

    Time frame: Week 4, 2 hours post-dose

  30. Plasma Concentrations of Osilodrostat (LCI699) at Week 6

    Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.

    Time frame: Week 6, 2 hours post-dose

  31. Plasma Concentrations of Osilodrostat (LCI699) at Week 8

    Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.

    Time frame: Week 8, 2 hours post-dose

  32. Plasma Concentrations of Osilodrostat (LCI699) at Week 10

    Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.

    Time frame: Week 10, 2 hours post-dose

  33. Plasma Concentrations of Osilodrostat (LCI699) at Week 12

    Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.

    Time frame: Week 12

  34. Plasma Concentrations of Osilodrostat (LCI699) at Week 16

    Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.

    Time frame: Week 16, 2 hours post-dose

  35. Plasma Concentrations of Osilodrostat (LCI699) at Week 20

    Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.

    Time frame: Week 20, 2 hours post-dose

  36. Plasma Concentrations of Osilodrostat (LCI699) at Week 24

    Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.

    Time frame: Week 24, 2 hours post-dose

07

Results

Posted Mar 11, 2020

Participant flow

Planned subjects: 10 subjects Actual enrolled: 9 subjects

Participant flow — Overall Study
MilestoneOsilodrostat
Started9
Completed week-12 (study period i)7
Discontinued at or prior to week-122
Completed week-12, did not enter per. ii3
Completed week-12, entered study per. ii4
Completed week-48 (study period ii)2
Discontinued at or prior to week482
Compl. wk-48, didn't enter opt. ext. per0
Compl. wk-48, entered opt. ext. period2
Completed optional extension period0
Discontinued study in optional ext. per.2
Completed3
Not completed6
Withdrew: Adverse event4
Withdrew: Subject/ guardian decision2

Outcome measures

PrimaryPercent Change in the Mean Urine Free Cortisol (mUFC) at the Individual Level at Week 12

Percent change from baseline in the mUFC at the individual patient level

Time frame:
Baseline, 12 weeks
Reported as:
Number · percentage change
Percent Change in the Mean Urine Free Cortisol (mUFC) at the Individual Level at Week 12
percentage changeOsilodrostat
AIMAH- Patient 1 (n=1)-99.0
Adrenal adenoma - Patient 1 (n=1)-97.8
Adrenal adenoma - Patient 2 (n=1)-94.5
Adrenal adenoma - Patient 3 (n=1)-91.5
Adrenal adenoma - Patient 4 (n=1)-81.8
Adrenal adenoma - Patient 5 (n=1)-52.6
Ectopic corticotropin syndrome - Patient 1 (n=1)-99.0
SecondaryPercent Change From Baseline in the mUFC at Individual Patient Level at Week 24 (Day 169) and Week 48 (Day 337)

Percent change from baseline in the mUFC at the individual patient level

Time frame:
Baseline, Week 24 (day 169) and Week 48 (day 337)
Reported as:
Number · percentage change
Percent Change From Baseline in the mUFC at Individual Patient Level at Week 24 (Day 169) and Week 48 (Day 337)
percentage changeOsilodrostat
AIMAH-Patient (Pt) 1: Week (Wk) 24 (n=1)-99.5
AIMAH-Patient 1:Wk 48 (n=1)-99.1
Adrenal adenoma-Patient 2: Wk 24(n=1)-85.2
Ectopic corticotropin syndrome-Pt 1: Wk 24(n=1)-91.6
Ectopic corticotropin syndrome-Pt 1: Wk 48(n=1)-91.0
SecondaryAbsolute Change From Baseline in the mUFC at Week 12 (Day 85), Week 24 (Day 169) and Week 48 (Day 337)

Absolute change from baseline in the mUFC

Time frame:
Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Reported as:
Median · nmol/24hr
Absolute Change From Baseline in the mUFC at Week 12 (Day 85), Week 24 (Day 169) and Week 48 (Day 337)
nmol/24hrOsilodrostat
Week 12 (day 85)( n = 7)-422.10 (-10487.5 to -157.0)
Week 24 (day 169) (n = 3)-7428.10 (-9702.0 to -367.9)
Week 48 (day 337) (n = 2)-8521.00 (-9640.5 to -7401.5)
SecondaryPercentage Change From Baseline in the mUFC at Week 12 (Day 85), Week 24 (Day 169) and Week 48 (Day 337)

Percent change from baseline in the mUFC

Time frame:
Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Reported as:
Median · percentage change
Percentage Change From Baseline in the mUFC at Week 12 (Day 85), Week 24 (Day 169) and Week 48 (Day 337)
percentage changeOsilodrostat
Week 12 (day 85)( n = 7)-94.47 (-99.0 to -52.6)
Week 24 (day 169) (n = 3)-91.57 (-99.5 to -85.2)
Week 48 (day 337) (n = 2)-95.04 (-99.1 to -91.0)
SecondaryPercentage of Participants With mUFC Response of Complete, Partial, and Overall Response

Complete response rate = percentage of participants who had mUFC≤ ULN; Partial response rate = Percentage of participants who had mUFC\>ULN and at least 50% reduction from baseline in mUFC. Overall response rate = Percentage of participants who had mUFC ≤ ULN or at least 50% reduction from baseline.

Time frame:
12, 24 and 48 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With mUFC Response of Complete, Partial, and Overall Response
Percentage of participantsOsilodrostat
Week 12: Complete responders66.7 (29.9 to 92.5)
Week 12: Partial responders11.1 (0.3 to 48.2)
Week 12: Overall responders77.8 (40.0 to 97.2)
Week 24: Complete responders (n =3)66.7 (9.4 to 99.2)
Week 24: Partial responders (n = 3)33.3 (0.8 to 90.6)
Week 24: Overall responders (n = 3)100 (29.2 to 100.0)
Week 48: Complete responders (n = 2)50.0 (1.3 to 98.7)
Week 48: Partial responders (n = 2)50.0 (1.3 to 98.7)
Week 48: Overall responders (n = 2)100 (15.8 to 100.0)
SecondaryAbsolute Change From Baseline in Morning Serum Cortisol at Individual Level

Absolute change from baseline in morning serum cortisol at the individual patient level

Time frame:
Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Reported as:
Number · nmol/L
Absolute Change From Baseline in Morning Serum Cortisol at Individual Level
nmol/LOsilodrostat
AIMAH-Patient (Pt) 1: Week (Wk) 12 (n = 1)-607
AIMAH-Patient 1: Wk 24 (n = 1)-571
AIMAH-Patient 1: Wk 48 (n = 1)-580
Adrenal adenoma-Patient 1: Wk 12 (n =1)-334
Adrenal adenoma-Patient 2: Wk 12(n =1)-157
Adrenal adenoma-Patient 2: Wk 24 (n =1)-135
Adrenal adenoma-Patient 3: Wk 12 (n =1)-300
Adrenal adenoma-Patient 4: Wk 12 (n =1)-30
Adrenal adenoma-Patient 5: Wk 12 (n =1)-13
Ectopic corticotropin syndrome-Pt 1: Wk 12 (n =1)-949
Ectopic corticotropin syndrome-Pt 1: Wk24 (n=1)-927
Ectopic corticotropin syndrome-Pt 1: Wk48 (n=1)-861
SecondaryPercentage Change From Baseline in Morning Serum Cortisol at Individual Level

Percentage change from baseline in morning serum cortisol at the individual patient level

Time frame:
Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Reported as:
Number · percentage change
Percentage Change From Baseline in Morning Serum Cortisol at Individual Level
percentage changeOsilodrostat
AIMAH-Patient (Pt) 1: Week (Wk) 12 (n = 1)-73.3
AIMAH-Patient 1: Wk 24 (n = 1)-69.0
AIMAH-Patient 1: Wk 48 (n = 1)-70.0
Adrenal adenoma-Patient 1: Wk 12 (n =1)-78.0
Adrenal adenoma-Patient 2: Wk 12(n =1)-50.8
Adrenal adenoma-Patient 2: Wk 24 (n =1)-43.7
Adrenal adenoma-Patient 3: Wk 12 (n =1)-56.1
Adrenal adenoma-Patient 4: Wk 12 (n =1)-8.7
Adrenal adenoma-Patient 5: Wk 12 (n =1)-3.5
Ectopic corticotropin syndrome-Pt 1: Wk 12 (n =1)-71.4
Ectopic corticotropin syndrome-Pt 1: Wk24 (n=1)-69.7
Ectopic corticotropin syndrome-Pt 1: Wk48 (n=1)-64.7
SecondaryAbsolute Change From Baseline in ACTH and Other Adrenal Steroid Hormones at Individual Level

Absolute change from baseline in several steroid hormones at individual levels: ACTH, Serum 11-deoxycorticosterone, Aldosterone, Estradiol

Time frame:
Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Reported as:
Number · pmol/L
Absolute Change From Baseline in ACTH and Other Adrenal Steroid Hormones at Individual Level
pmol/LACTHSerum 11-deoxycorticosteroneAldosteroneEstradiol
AIMAH-Patient (Pt) 1 Wk 12 (n=1,1,1,1)0217952705
AIMAH-Pt 1 Wk 24 (n=1,1,1,1)03601236235
AIMAH-Pt 1 Wk 48 (n=1,1,1,1)0454170400
Adrenal adenoma-Pt 1 Wk 12 (n=1,1,1,1)1.12966-27-404
Adrenal adenoma-Pt 2 Wk 12 (n=1,1,1,1)05145-9814
Adrenal adenoma-Pt 2 Wk 24(n=1,1,1,1)00450-4
Adrenal adenoma-Pt 3 Wk 12 (n=1,1,1,1)00-14777
Adrenal adenoma-Pt 4 Wk 12 (n=1,1,1,1)0787318
Adrenal adenoma-Pt 5 Wk 12 (n=1,1,1,1)000-11
Ectopic ACTH syndrome-Pt 1: Wk 12 (n=1,1,1,1)-67.7-69614551
Ectopic ACTH syndrome-Pt 1: Wk 24 (n=1,1,1,1)-47.3-9140-11
Ectopic ACTH syndrome-Pt 1: Wk 48 (n=1,1,1,1)13.3-913711
SecondaryPercentage Change From Baseline in ACTH and Other Adrenal Steroid Hormones at Individual Level

Percent change from baseline in several steroid hormones at individual levels: ACTH, Serum 11-deoxycorticosterone, Aldosterone, Estradiol

Time frame:
Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Reported as:
Number · percentage change
Percentage Change From Baseline in ACTH and Other Adrenal Steroid Hormones at Individual Level
percentage changeACTHSerum 11-deoxycorticosteroneAldosteroneEstradiol
AIMAH-Patient (Pt) 1 Wk 12 (n =0,1,0,1)—118.0—1282
AIMAH-Pt 1 Wk 24 (n=0,1,0,1)—195.1—427.3
AIMAH-Pt 1 Wk 48 (n=0,1,0,1)—24.6—727.3
Adrenal adenoma-Pt 1 Wk 12 (n =0,0,1,1)——-13.9-53.7
Adrenal adenoma-Pt 2 Wk 12 (n =0,0,1,1)——-1001.9
Adrenal adenoma-Pt 2 Wk 24 (n =0,0,1,1)——45.9-1.9
Adrenal adenoma-Pt 3 Wk 12 (n =0,0,1,1)——-75.0513.3
Adrenal adenoma-Pt 4 Wk 12 (n =0,0,1,1)——10.0120.0
Adrenal adenoma-Pt 5 Wk 12 (n =0,0,0,1)———-100
Ectopic ACTH syndrome-Pt 1: Wk 12 (n=1,1,0,1)-71.6-100—72.9
Ectopic ACTH syndrome-Pt 1: Wk 24 (n=1,1,0,1)-50.0-13.1—-15.7
Ectopic ACTH syndrome-Pt 1: Wk 48 (n=1,1,0,1)14.1-13.1—15.7
SecondaryAbsolute Change From Baseline in Other Adrenal Steroid Hormones at Individual Levels

Absolute change from baseline in several steroid hormones at individual levels: Serum 11-deoxycortisol, Testosterone

Time frame:
Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Reported as:
Number · nmol/L
Absolute Change From Baseline in Other Adrenal Steroid Hormones at Individual Levels
nmol/LSerum 11-deoxycortisolTestosterone
AIMAH-Patient (Pt) 1 Wk 12 (n = 1,1)-4.350.76
AIMAH-Pt 1 Wk 24 (n = 1,1)-8.50.66
AIMAH-Pt 1 Wk 48 (n = 1,1)-15.54-0.03
Adrenal adenoma-Pt 1 Wk 12 (n = 1,1)6.910.31
Adrenal adenoma-Pt 2 Wk 12 (n = 1,1)2.810.11
Adrenal adenoma-Pt 2 Wk 24 (n = 1,1)-0.64-0.35
Adrenal adenoma-Pt 3 Wk 12 (n = 1,1)7.340.42
Adrenal adenoma-Pt 4 Wk 12 (n = 1,1)3.50.03
Adrenal adenoma-Pt 5 Wk 12 (n = 1,1)-1.390
Ectopic ACTH syndrome-Pt 1 Wk 12(n = 1,1)-15.815.83
Ectopic ACTH syndrome-Pt 1 Wk 24 (n = 1,1)-12.41-2.71
Ectopic ACTH syndrome-Pt 1 Wk 48 (n = 1,1)-2.52-2.01
SecondaryPercentage Change From Baseline in Other Adrenal Steroid Hormones at Individual Levels

Percent change from baseline in several steroid hormones at individual levels: Serum 11-deoxycortisol, Testosterone

Time frame:
Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Reported as:
Number · percentage change
Percentage Change From Baseline in Other Adrenal Steroid Hormones at Individual Levels
percentage changeSerum 11-deoxycortisolTestosterone
AIMAH-Patient (Pt) 1 Wk 12 (n=1, 1)-17.873.1
AIMAH-Pt 1 Wk 24 (n=1, 1)-34.963.5
AIMAH-Pt 1 Wk 48 (n=1, 1)-63.7-2.9
Adrenal adenoma-Pt 1 Wk 12 (n=1,1)143.7100.0
Adrenal adenoma-Pt 2 Wk 12 (n=1,1)108.910.6
Adrenal adenoma-Pt 2 Wk 24 (n=1,1)-24.8-33.7
Adrenal adenoma-Pt 3 Wk 12 (n=1, 1)127.293.3
Adrenal adenoma-Pt 4 Wk 12 (n=1, 1)267.214.3
Adrenal adenoma-Pt 5 Wk 12 (n=1,1)-43.20.0
Ectopic ACTH syndrome-Pt 1 Wk 12 (n=1, 1)-64.896.5
Ectopic ACTH syndrome-Pt 1 Wk 24 (n=1, 1)-50.9-44.9
Ectopic ACTH syndrome-Pt 1 Wk 48 (n=1, 1)-10.3-33.3
SecondaryAbsolute Change From Baseline in Cardiovascular-related Metabolic Parameter, Fasting Glucose, at Individual Level

Absolute change in cardiovascular-related metabolic parameter fasting glucose, associated with Cushing's syndrome (CS)

Time frame:
Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Reported as:
Number · mmol/L
Absolute Change From Baseline in Cardiovascular-related Metabolic Parameter, Fasting Glucose, at Individual Level
mmol/LOsilodrostat
AIMAH-Patient (Pt) 1 Wk 12 (n =1)-0.78
AIMAH-Patient (Pt) 1 Wk 24 (n =1)-0.84
AIMAH-Patient (Pt) 1 Wk 48 (n =1)-0.78
Adrenal adenoma-Pt 1 Wk 12 (n =1)1.22
Adrenal adenoma-Pt 2 Wk 12 (n =1)-1.89
Adrenal adenoma-Pt 2 Wk 24 (n =1)0.22
Adrenal adenoma-Pt 3 Wk 12 (n =1)-0.28
Adrenal adenoma-Pt 4 Wk 12 (n =1)-0.67
Adrenal adenoma-Pt 5 Wk 12 (n =1)-0.05
Ectopic ACTH syndrome-Pt 1 Wk 12 (n =1)-0.33
Ectopic ACTH syndrome-Pt 1 Wk 24 (n =1)-0.39
Ectopic ACTH syndrome-Pt 1 Wk 48 (n =1)0.06
SecondaryPercentage Change From Baseline in Cardiovascular-related Metabolic Parameter, Fasting Glucose, at Individual Level

Percentasge change in cardiovascular-related metabolic parameter fasting glucose, associated with Cushing's syndrome (CS)

Time frame:
Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Reported as:
Number · percentage change
Percentage Change From Baseline in Cardiovascular-related Metabolic Parameter, Fasting Glucose, at Individual Level
percentage changeOsilodrostat
AIMAH-Patient (Pt) 1 Wk 12 (n =1)-15.3
AIMAH-Patient (Pt) 1 Wk 24 (n =1)-16.4
AIMAH-Patient (Pt) 1 Wk 48 (n =1)-15.3
Adrenal adenoma-Pt 1 Wk 12 (n =1)24.2
Adrenal adenoma-Pt 2 Wk 12 (n =1)-27.2
Adrenal adenoma-Pt 2 Wk 24 (n =1)3.2
Adrenal adenoma-Pt 3 Wk 12 (n =1)-5.0
Adrenal adenoma-Pt 4 Wk 12 (n =1)-11.3
Adrenal adenoma-Pt 5 Wk 12 (n =1)-0.9
Ectopic ACTH syndrome-Pt 1 Wk 12 (n =1)-5.9
Ectopic ACTH syndrome-Pt 1 Wk 24 (n =1)-7.0
Ectopic ACTH syndrome-Pt 1 Wk 48 (n =1)1.1
SecondaryAbsolute Change From Baseline in Cardiovascular-related Metabolic Parameter, HbA1c, at Individual Level

Absolute change in cardiovascular-related metabolic parameter HbA1c associated with Cushing's syndrome (CS)

Time frame:
Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Reported as:
Number · percentage of HbA1c
Absolute Change From Baseline in Cardiovascular-related Metabolic Parameter, HbA1c, at Individual Level
percentage of HbA1cOsilodrostat
AIMAH-Patient (Pt) 1 Wk 12 (n=1)-0.1
AIMAH-Pt 1 Wk 24 (n=1)-0.1
AIMAH-Pt 1 Wk 48 (n=1)-0.2
Adrenal adenoma-Pt 1 Wk 12 (n=1)0.3
Adrenal adenoma-Pt 2 Wk 12 (n=1)-0.4
Adrenal adenoma-Pt 2 Wk 24 (n=1)-0.7
Adrenal adenoma-Pt 3 Wk 12 (n=1)-1.4
Adrenal adenoma-Pt 4 Wk 12 (n=1)-0.9
Adrenal adenoma-Pt 5 Wk 12 (n=1)-0.1
Ectopic ACTH syndrome-Pt 1 Wk 12 (n=1)0.3
Ectopic ACTH syndrome-Pt 1 Wk 24 (n=1)0.5
Ectopic ACTH syndrome-Pt 1 Wk 48 (n=1)0.8
SecondaryPercentage Change From Baseline in Cardiovascular-related Metabolic Parameter, HbA1c, at Individual Level

Percentage change in cardiovascular-related metabolic parameter HbA1c associated with Cushing's syndrome (CS)

Time frame:
Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Reported as:
Number · percentage change
Percentage Change From Baseline in Cardiovascular-related Metabolic Parameter, HbA1c, at Individual Level
percentage changeOsilodrostat
AIMAH-Patient (Pt) 1 Wk 12 (n=1)-1.8
AIMAH-Pt 1 Wk 24 (n=1)-1.8
AIMAH-Pt 1 Wk 48 (n=1)-3.6
Adrenal adenoma-Pt 1 Wk 12 (n=1)6.2
Adrenal adenoma-Pt 2 Wk 12 (n=1)-6.5
Adrenal adenoma-Pt 2 Wk 24 (n=1)-11.3
Adrenal adenoma-Pt 3 Wk 12 (n=1)-20.3
Adrenal adenoma-Pt 4 Wk 12 (n=1)-12.2
Adrenal adenoma-Pt 5 Wk 12 (n=1)-1.5
Ectopic ACTH syndrome-Pt 1 Wk 12 (n=1)5.4
Ectopic ACTH syndrome-Pt 1 Wk 24 (n=1)8.9
Ectopic ACTH syndrome-Pt 1 Wk 48 (n=1)14.3
SecondaryAbsolute Change From Baseline in Cardiovascular-related Metabolic Parameters, Cholesterol, HDL Cholesterol, LDL Cholesterol & Triglycerides, at Individual Level

Absolute change in cardiovascular-related metabolic parameters: cholesterol, HDL cholesterol, LDL cholesterol \& triglycerides, associated with Cushing's syndrome (CS)

Time frame:
Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Reported as:
Number · mmol/L
Absolute Change From Baseline in Cardiovascular-related Metabolic Parameters, Cholesterol, HDL Cholesterol, LDL Cholesterol & Triglycerides, at Individual Level
mmol/LCholesterolHDL CholesterolLDL CholesterolTriglycerides
AIMAH-Patient (Pt) 1 Wk 12 (n =1,1,1,1)-0.67-0.850.21-0.87
AIMAH-Pt 1 Wk 24 (n =1,1,1,1)-0.65-1.010.18-0.64
AIMAH-Pt 1 Wk 48 (n =1,1,1,1)-0.72-0.57-0.08-0.76
Adrenal adenoma-Pt 1 Wk 12 (n =1,1,1,1)-1.56-0.26-1.11-1.42
Adrenal adenoma-Pt 2 Wk 12 (n =1,1,1,1)-0.54-0.64-0.260.11
Adrenal adenoma-Pt 2 Wk 24 (n =1,1,1,1)0.26-0.330.310.08
Adrenal adenoma-Pt 3 Wk 12 (n =1,1,1,1)-0.55-0.16-0.19-1.36
Adrenal adenoma-Pt 4 Wk 12 (n =1,1,1,1)1.090.180.720.58
Adrenal adenoma-Pt 5 Wk 12 (n =1,1,1,1)-0.39-0.21-0.180.44
Ectopic ACTH syndrome-Pt 1 Wk 12(n =1,1,1,1)-0.160.16-0.11-0.47
Ectopic ACTH syndrome-Pt 1 Wk 24 (n =1,1,1,1)-0.260.49-0.29-0.83
Ectopic ACTH syndrome-Pt 1 Wk 48 (n =1,1,1,1)-0.080.29-0.310.22
SecondaryPercentage Change From Baseline in Cardiovascular-related Metabolic Parameters, Cholesterol, HDL Cholesterol, LDL Cholesterol & Triglycerides, at Individual Level

Percent change in cardiovascular-related metabolic parameters: cholesterol, HDL cholesterol, LDL cholesterol \& triglycerides, associated with Cushing's syndrome (CS)

Time frame:
Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Reported as:
Number · percentage change
Percentage Change From Baseline in Cardiovascular-related Metabolic Parameters, Cholesterol, HDL Cholesterol, LDL Cholesterol & Triglycerides, at Individual Level
percentage changeCholesterolHDL CholesterolLDL CholesterolTriglycerides
AIMAH-Patient (Pt) 1 Wk 12 (n =1,1,1,1)-11.1-33.26.3-49.4
AIMAH-Pt 1 Wk 24 (n =1,1,1,1)-10.7-39.55.4-36.4
AIMAH-Pt 1 Wk 48 (n =1,1,1,1)-11.9-22.3-2.4-43.2
Adrenal adenoma-Pt 1 Wk 12 (n =1,1,1,1)-23.0-27.1-24.9-28.8
Adrenal adenoma-Pt 2 Wk 12 (n =1,1,1,1)-11.9-34.4-10.612.5
Adrenal adenoma-Pt 2 Wk 24 (n =1,1,1,1)5.7-17.712.69.1
Adrenal adenoma-Pt 3 Wk 12 (n =1,1,1,1)-9.5-9.4-5.5-56.7
Adrenal adenoma-Pt 4 Wk 12 (n =1,1,1,1)23.015.526.546.8
Adrenal adenoma-Pt 5 Wk 12 (n =1,1,1,1)-8.7-11.4-9.333.3
Ectopic ACTH syndrome-Pt 1 Wk 12(n =1,1,1,1)-3.812.4-4.5-32.0
Ectopic ACTH syndrome-Pt 1 Wk 24 (n =1,1,1,1)-6.238.0-11.8-56.5
Ectopic ACTH syndrome-Pt 1 Wk 48 (n =1,1,1,1)-1.922.5-12.615.0
SecondaryAbsolute Change From Baseline in Cardiovascular-related Metabolic Parameter, BMI, at Individual Level

Absolute change in cardiovascular-related metabolic parameter: BMI, associated with Cushing's syndrome (CS)

Time frame:
Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Reported as:
Number · kg/m^2
Absolute Change From Baseline in Cardiovascular-related Metabolic Parameter, BMI, at Individual Level
kg/m^2Osilodrostat
AIMAH-Patient (Pt) 1 Wk 12 (n =1)-0.5
AIMAH-Pt 1 Wk 24 (n =1)-2.3
AIMAH-Pt 1 Wk 48 (n =1)-1.6
Adrenal adenoma-Pt 1 Wk 12 (n =1)0.6
Adrenal adenoma-Pt 2 Wk 12 (n =1)-1.2
Adrenal adenoma-Pt 2 Wk 24 (n =1)-3.6
Adrenal adenoma-Pt 3 Wk 12 (n =1)0.7
Adrenal adenoma-Pt 4 Wk 12 (n =1)0.2
Adrenal adenoma-Pt 5 Wk 12 (n =1)0.1
Ectopic ACTH syndrome-Pt 1 Wk 12(n =1)1.8
Ectopic ACTH syndrome-Pt 1 Wk 24 (n =1)3.0
Ectopic ACTH syndrome-Pt 1 Wk 48 (n =1)3.6
SecondaryPercentage Change From Baseline in Cardiovascular-related Metabolic Parameter, BMI, at Individual Level

Percent change in cardiovascular-related metabolic parameter: BMI, associated with Cushing's syndrome (CS)

Time frame:
Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Reported as:
Number · percentage change
Percentage Change From Baseline in Cardiovascular-related Metabolic Parameter, BMI, at Individual Level
percentage changeOsilodrostat
AIMAH-Patient (Pt) 1 Wk 12 (n =1)-2.1
AIMAH-Pt 1 Wk 24 (n =1)-9.6
AIMAH-Pt 1 Wk 48 (n =1)-6.7
Adrenal adenoma-Pt 1 Wk 12 (n =1)1.9
Adrenal adenoma-Pt 2 Wk 12 (n =1)-3.1
Adrenal adenoma-Pt 2 Wk 24 (n =1)-9.4
Adrenal adenoma-Pt 3 Wk 12 (n =1)3.3
Adrenal adenoma-Pt 4 Wk 12 (n =1)0.9
Adrenal adenoma-Pt 5 Wk 12 (n =1)0.5
Ectopic ACTH syndrome-Pt 1 Wk 12(n =1)7.4
Ectopic ACTH syndrome-Pt 1 Wk 24 (n =1)12.3
Ectopic ACTH syndrome-Pt 1 Wk 48 (n =1)14.8
SecondaryAbsolute Change From Baseline in Cardiovascular-related Metabolic Parameter, Waist Circumference, at Individual Level

Absolute change in cardiovascular-related metabolic parameter: Waist circumference, associated with Cushing's syndrome (CS)

Time frame:
Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Reported as:
Number · cm
Absolute Change From Baseline in Cardiovascular-related Metabolic Parameter, Waist Circumference, at Individual Level
cmOsilodrostat
AIMAH-Patient (Pt)1 Wk 12 (n=1)-2.0
AIMAH-Pt1 Wk 24 (n=1)-7.5
AIMAH-Pt1 Wk 48 (n=1)-5.5
Adrenal adenoma-Pt 1 Wk 12 (n=1)-2.0
Adrenal adenoma-Pt 2 Wk 12 (n=1)-1.0
Adrenal adenoma-Pt 2 Wk 24 (n=1)-8.0
Adrenal adenoma-Pt 3 Wk 12 (n=1)-4.0
Adrenal adenoma-Pt 4 Wk 12 (n=1)1.0
Adrenal adenoma-Pt 5 Wk 12 (n=1)-0.3
Ectopic ACTH syndrome-Pt 1 Wk 12 (n=1)2.5
Ectopic ACTH syndrome-Pt 1 Wk 24 (n=1)11.0
Ectopic ACTH syndrome-Pt 1 Wk 48 (n=1)9.5
SecondaryPercentage Change From Baseline in Cardiovascular-related Metabolic Parameter, Waist Circumference, at Individual Level

Percent change in cardiovascular-related metabolic parameter: Waist circumference, associated with Cushing's syndrome (CS)

Time frame:
Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Reported as:
Number · percentage change
Percentage Change From Baseline in Cardiovascular-related Metabolic Parameter, Waist Circumference, at Individual Level
percentage changeOsilodrostat
AIMAH-Patient (Pt)1 Wk 12 (n=1)-2.4
AIMAH-Pt1 Wk 24 (n=1)-9.0
AIMAH-Pt1 Wk 48 (n=1)-6.6
Adrenal adenoma-Pt 1 Wk 12 (n=1)-1.8
Adrenal adenoma-Pt 2 Wk 12 (n=1)-0.9
Adrenal adenoma-Pt 2 Wk 24 (n=1)-7.1
Adrenal adenoma-Pt 3 Wk 12 (n=1)-4.9
Adrenal adenoma-Pt 4 Wk 12 (n=1)1.1
Adrenal adenoma-Pt 5 Wk 12 (n=1)-0.4
Ectopic ACTH syndrome-Pt 1 Wk 12 (n=1)2.9
Ectopic ACTH syndrome-Pt 1 Wk 24 (n=1)12.9
Ectopic ACTH syndrome-Pt 1 Wk 48 (n=1)11.1
SecondaryAbsolute Change From Baseline in Cardiovascular-related Metabolic Parameter, Sitting Blood Pressure (BP) at Individual Level

Absolute change in cardiovascular-related metabolic parameter: sitting systolic BP \& sitting diastolic BP, associated with Cushing's syndrome (CS)

Time frame:
Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Reported as:
Number · mmHg
Absolute Change From Baseline in Cardiovascular-related Metabolic Parameter, Sitting Blood Pressure (BP) at Individual Level
mmHgSitting Systolic BPSitting Diastolic BP
AIMAH-Patient (Pt) 1Wk 12 (n =1, 1)-44.3-31.0
AIMAH-Patient (Pt) 1 Wk 24 (n =1, 1)-48.34-32.66
AIMAH-Patient (Pt) 1 Wk 48 (n =1, 1)-40.34-19.0
Adrenal adenoma-Pt 1 Wk 12 (n=1,1)11.67-3.67
Adrenal adenoma-Pt 2 Wk 12 (n=1,1)-50.67-37.0
Adrenal adenoma-Pt 2 Wk 24 (n=1,1)-32.33-26.66
Adrenal adenoma-Pt 3 Wk 12 (n=1,1)-16.0-6.67
Adrenal adenoma-Pt 4 Wk 12 (n=1,1)-6.677.33
Adrenal adenoma-Pt 5 Wk 12 (n=1,1)11.03.33
Ectopic ACTH syndrome-Pt 1 Wk 12(n=1,1)-17.67-13.67
Ectopic ACTH syndrome-Pt 1 Wk 24 (n=1,1)4.334.0
Ectopic ACTH syndrome-Pt 1 Wk 48 (n=1,1)-1.0-0.67
SecondaryPercentage Change From Baseline in Cardiovascular-related Metabolic Parameter, Sitting Blood Pressure (BP) at Individual Level

Percentage change in cardiovascular-related metabolic parameter: sitting systolic BP \& sitting diastolic BP, associated with Cushing's syndrome

Time frame:
Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Reported as:
Number · percentage change
Percentage Change From Baseline in Cardiovascular-related Metabolic Parameter, Sitting Blood Pressure (BP) at Individual Level
percentage changeSitting Systolic BPSitting Diastolic BP
AIMAH-Patient (Pt) 1Wk 12 (n =1, 1)-31.1-32.5
AIMAH-Patient (Pt) 1 Wk 24 (n =1, 1)-33.9-34.3
AIMAH-Patient (Pt) 1 Wk 48 (n =1, 1)-28.3-19.9
Adrenal adenoma-Pt 1 Wk 12 (n=1,1)9.2-4.1
Adrenal adenoma-Pt 2 Wk 12 (n=1,1)-31.3-33.2
Adrenal adenoma-Pt 2 Wk 24 (n=1,1)-20.0-23.9
Adrenal adenoma-Pt 3 Wk 12 (n=1,1)-12.3-8.9
Adrenal adenoma-Pt 4 Wk 12 (n=1,1)-4.39.9
Adrenal adenoma-Pt 5 Wk 12 (n=1,1)9.35.1
Ectopic ACTH syndrome-Pt 1 Wk 12(n=1,1)-14.1-16.5
Ectopic ACTH syndrome-Pt 1 Wk 24 (n=1,1)3.44.8
Ectopic ACTH syndrome-Pt 1 Wk 48 (n=1,1)-0.8-0.8
SecondaryTotal Scores in Patient-Reported Outcomes Health-related Quality of Life (QoL) as Assessed by Cushing QoL at Individual Level

The Cushing's Disease Health-Related Quality of Life Questionnaire (Cushing QoL) (version 1.0) was developed to evaluate quality of life in patients with Cushing's syndrome (Webb et al 2008). The Cushing QoL is comprised of 12 items that capture patient responses on seven concepts: daily activities, healing and pain, mood and self-confidence, social concerns, physical appearance, memory and concern about the future. Each questionnaire of the Cushing QOL has a scale of 1-5 where '1' corresponding to 'Always' or 'Very much' and '5' to 'Never' or 'Not at all'. The lower the score, the greater the impact on HRQoL. The score is the sum of all the item response and can range from 12 (worst) to 60 points (best).

Time frame:
Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Reported as:
Number · scores on a scale
Total Scores in Patient-Reported Outcomes Health-related Quality of Life (QoL) as Assessed by Cushing QoL at Individual Level
scores on a scaleOsilodrostat
AIMAH-Patient 1: Week (Wk) 12 (n=1)48
AIMAH-Patient 1: Wk 24 (n=1)51
AIMAH-Patient 1: Wk 48 (n=1)47
Adrenal adenoma-Patient 1: Wk 12(n=1)29
Adrenal adenoma-Patient 2: Wk 12(n=1)18
Adrenal adenoma-Patient 2: Wk 24 (n = 1)22
Adrenal adenoma-Patient 3: Wk 12 (n =1)29
Adrenal adenoma-Patient 4: Wk 12 (n =1)38
Adrenal adenoma-Patient 5: Wk 12 (n=1)45
Ectopic corticotropin syndrome-Pt 1: Wk 12 (n =1)31
Ectopic corticotropin syndrome-Pt 1: Wk 24 (n =1)33
Ectopic corticotropin syndrome-Pt 1: Wk 48 (n =1)23
SecondaryTotal Scores in Patient-Reported Outcomes Health-related Quality of Life (QoL) as Assessed by Beck Depression Inventory II (BDI-ll) Depression Score at Individual Level

The Beck Depression Inventory II (BDI-II) is a patient reported instrument that consists of 21 items designed to assess the intensity of depression in clinical \& normal patients in the preceding two weeks. Each item is a list of four statements arranged in increasing severity about a particular symptom of depression. Each of 21 items corresponds to a symptom of depression and the sum of total score will be calculated where each item has a four-point scale ranging from 0 to 3, leading to a total score from zero to 63.

Time frame:
Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Reported as:
Number · scores on a scale
Total Scores in Patient-Reported Outcomes Health-related Quality of Life (QoL) as Assessed by Beck Depression Inventory II (BDI-ll) Depression Score at Individual Level
scores on a scaleOsilodrostat
AIMAH-Patient 1: Week (Wk) 12 (n =1)4
AIMAH-Patient 1: Wk 24 (n =1)15
AIMAH-Patient 1: Wk 48 (n =1)12
Adrenal adenoma-Patient 1: Wk 12 (n =1)33
Adrenal adenoma-Patient 2: Wk 12 (n =1)35
Adrenal adenoma-Patient 2: Wk 24 (n =1)37
Adrenal adenoma-Patient 3: Wk 12 (n =1)30
Adrenal adenoma-Patient 4: Wk 12 (n =1)26
Adrenal adenoma-Patient 5: Wk 12 (n =1)10
Ectopic corticotropin syndrome-Pt 1: Wk 12 (n =1)9
Ectopic corticotropin syndrome-Pt 1: Wk 24 (n =1)10
Ectopic corticotropin syndrome-Pt 1: Wk 48 (n =1)22
SecondaryPlasma Concentrations of Osilodrostat (LCI699) at Week 0

Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.

Time frame:
Week 0
Reported as:
Mean · ng/mL
Plasma Concentrations of Osilodrostat (LCI699) at Week 0
ng/mLOsilodrostat 1mgOsilodrostat 2mgOsilodrostat 3mgOsilodrostat 5mg
Week 0: 0.75 hour post-dose0.971 ± NA0.405 ± 0.673——
Week 0: 2 hours post-dose5.11 ± NA5.29 ± 4.94——
Week 0: 4 hours post-dose3.77 ± NA8.12 ± 2.36——
SecondaryPlasma Concentrations of Osilodrostat (LCI699) at Week 1

Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.

Time frame:
Week 1, 2 hours post-dose
Reported as:
Mean · ng/mL
Plasma Concentrations of Osilodrostat (LCI699) at Week 1
ng/mLOsilodrostat 1mgOsilodrostat 2mgOsilodrostat 3mgOsilodrostat 5mg
Plasma Concentrations of Osilodrostat (LCI699) at Week 110.9 ± NA10.5 ± 6.5721.3 ± NA22.3 ± 14.2
SecondaryPlasma Concentrations of Osilodrostat (LCI699) at Week 2

Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.

Time frame:
Week 2
Reported as:
Mean · ng/mL
Plasma Concentrations of Osilodrostat (LCI699) at Week 2
ng/mLOsilodrostat 1mgOsilodrostat 2mgOsilodrostat 3mgOsilodrostat 5mg
Week 2: 0.75 hour post-dose3.89 ± 2.763.69 ± 3.333.1 ± 19.234.9 ± 34.6
Week 2: 2 hours post-dose8.93 ± 2.3614.3 ± 7.6421.3 ± 4.5333.6 ± 8.84
Week 2: 4 hours post-dose7.01 ± 2.6911.1 ± NA13.6 ± 3.8929.2 ± 0.354
SecondaryPlasma Concentrations of Osilodrostat (LCI699) at Week 3

Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.

Time frame:
Week 3, 2 hours post-dose
Reported as:
Mean · ng/mL
Plasma Concentrations of Osilodrostat (LCI699) at Week 3
ng/mLOsilodrostat 1mgOsilodrostat 2mgOsilodrostat 3mgOsilodrostat 5mg
Plasma Concentrations of Osilodrostat (LCI699) at Week 37.09 ± 2.077.62 ± NA23.2 ± NA37.8 ± 0.849
SecondaryPlasma Concentrations of Osilodrostat (LCI699) at Week 4

Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.

Time frame:
Week 4, 2 hours post-dose
Reported as:
Mean · ng/mL
Plasma Concentrations of Osilodrostat (LCI699) at Week 4
ng/mLOsilodrostat 1mgOsilodrostat 2mgOsilodrostat 3mgOsilodrostat 5mg
Plasma Concentrations of Osilodrostat (LCI699) at Week 44.08 ± 2.619.91 ± 3.53—24.0 ± 21.00
SecondaryPlasma Concentrations of Osilodrostat (LCI699) at Week 6

Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.

Time frame:
Week 6, 2 hours post-dose
Reported as:
Mean · ng/mL
Plasma Concentrations of Osilodrostat (LCI699) at Week 6
ng/mLOsilodrostat 1mgOsilodrostat 2mgOsilodrostat 3mgOsilodrostat 5mg
Plasma Concentrations of Osilodrostat (LCI699) at Week 66.74 ± 2.4212.7 ± 9.08—31.7 ± NA
SecondaryPlasma Concentrations of Osilodrostat (LCI699) at Week 8

Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.

Time frame:
Week 8, 2 hours post-dose
Reported as:
Mean · ng/mL
Plasma Concentrations of Osilodrostat (LCI699) at Week 8
ng/mLOsilodrostat 1mgOsilodrostat 2mgOsilodrostat 3mgOsilodrostat 5mg
Plasma Concentrations of Osilodrostat (LCI699) at Week 83.35 ± 2.7513.9 ± NA——
SecondaryPlasma Concentrations of Osilodrostat (LCI699) at Week 10

Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.

Time frame:
Week 10, 2 hours post-dose
Reported as:
Mean · ng/mL
Plasma Concentrations of Osilodrostat (LCI699) at Week 10
ng/mLOsilodrostat 1mgOsilodrostat 2mgOsilodrostat 3mgOsilodrostat 5mg
Plasma Concentrations of Osilodrostat (LCI699) at Week 104.73 ± 1.2611.3 ± 4.57——
SecondaryPlasma Concentrations of Osilodrostat (LCI699) at Week 12

Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.

Time frame:
Week 12
Reported as:
Mean · ng/mL
Plasma Concentrations of Osilodrostat (LCI699) at Week 12
ng/mLOsilodrostat 1mgOsilodrostat 2mgOsilodrostat 3mgOsilodrostat 5mg
Week 12: 0.75 hour post-dose0.382 ± 0.1713.1 ± NA——
Week 12: 2 hours post-dose4.62 ± 2.519.98 ± NA——
Week 12: 4 hours post-dose3.58 ± 2.36.57 ± NA——
SecondaryPlasma Concentrations of Osilodrostat (LCI699) at Week 16

Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.

Time frame:
Week 16, 2 hours post-dose
Reported as:
Mean · ng/mL
Plasma Concentrations of Osilodrostat (LCI699) at Week 16
ng/mLOsilodrostat 1mgOsilodrostat 2mgOsilodrostat 3mgOsilodrostat 5mg
Plasma Concentrations of Osilodrostat (LCI699) at Week 165.71 ± 1.33———
SecondaryPlasma Concentrations of Osilodrostat (LCI699) at Week 20

Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.

Time frame:
Week 20, 2 hours post-dose
Reported as:
Mean · ng/mL
Plasma Concentrations of Osilodrostat (LCI699) at Week 20
ng/mLOsilodrostat 1mgOsilodrostat 2mgOsilodrostat 3mgOsilodrostat 5mg
Plasma Concentrations of Osilodrostat (LCI699) at Week 200.794 ± NA———
SecondaryPlasma Concentrations of Osilodrostat (LCI699) at Week 24

Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.

Time frame:
Week 24, 2 hours post-dose
Reported as:
Mean · ng/mL
Plasma Concentrations of Osilodrostat (LCI699) at Week 24
ng/mLOsilodrostat 1mgOsilodrostat 2mgOsilodrostat 3mgOsilodrostat 5mg
Plasma Concentrations of Osilodrostat (LCI699) at Week 246.51 ± 2.14———

Adverse events

Collected over Adverse events (AEs) were collected from first dose of study treatment until end of study treatment plus 30 days post treatment, up to maximum duration of 68.0 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Osilodrostat0/9 (0%)4/9 (44.4%)9/9 (100%)
Most frequent serious events
Most frequent serious events
EventOsilodrostat
Adrenal insufficiencyEndocrine disorders2/9
Myocardial infarctionCardiac disorders1/9
PneumoniaInfections and infestations1/9
Psychiatric symptomPsychiatric disorders1/9
Most frequent other events
Showing 10 of 43
Most frequent other events
EventOsilodrostat
Adrenal insufficiencyEndocrine disorders5/9
MalaiseGeneral disorders3/9
NasopharyngitisInfections and infestations3/9
Gamma-glutamyltransferase increasedInvestigations3/9
ConstipationGastrointestinal disorders2/9
Alanine aminotransferase increasedInvestigations2/9
Aspartate aminotransferase increasedInvestigations2/9
Blood alkaline phosphatase increasedInvestigations2/9
HypokalaemiaMetabolism and nutrition disorders2/9
Dermatitis acneiformSkin and subcutaneous tissue disorders2/9

Baseline characteristics

Full Analysis Set (FAS): Comprised of all enrolled patients who received at least one dose of osilodrostat.

Age, Continuous
Age, Continuous(years)Osilodrostat
Mean51.0 ± 18.17
Sex: Female, Male
Sex: Female, Male(Participants)Osilodrostat
Female7
Male2
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Osilodrostat
Japanese9
Type of disease
Type of disease(Participants)Osilodrostat
ACTH-Independent Macronodular Adrena;l Hyperplasia1
Adrenal Adenoma5
Ectopic Corticotropin Syndrome3
08

Study locations

4 sites
  • Novartis Investigative Site
    Fukushima city, Fukushima 960 1295, Japan
  • Novartis Investigative Site
    Yokohama, Kanagawa 245-8575, Japan
  • Novartis Investigative Site
    Sendai city, Miyagi 980 8574, Japan
  • Novartis Investigative Site
    Chiba, 260 8677, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data is currently available according to the process described on www.clinicalstudydatarequest.com

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2015 to primary completion in Jun 2018, 32 months.

Results were first posted in Mar 2020, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2015
First posted
Jun 10, 2015
StartActual
Sep 24, 2015
Primary completionActual
Jun 7, 2018
CompletionActual
Oct 29, 2018
Results first posted
Mar 11, 2020
Last update
May 6, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02468193
Responsible party
Sponsor
First posted
Jun 10, 2015
Start date
Sep 24, 2015
Primary completion
Jun 7, 2018
Completion
Oct 29, 2018
Results posted
Mar 11, 2020
Last update
May 6, 2020

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osilodrostat

Start the discussion